DB
BIOA

Dmitry Balyasny’s BioAge Labs BIOA Stock Holding History

Dmitry Balyasny’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Sell
702,858
-624,687
-47% -$11.3M 0.02% 793
2026
Q1 		$23.2M Buy
+1,327,545
New +$25.6M 0.03% 623
2024
Q4 		– Sell
-120,000
Closed -$2.5M – 3354
2024
Q3 		$2.5M Buy
+120,000
New +$2.4M ﹤0.01% 1585

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Dmitry Balyasny's BIOA Position: Q2 2026 in Review

Dmitry Balyasny reduced its BioAge Labs (BIOA) stake by 47% in Q2 2026, selling an estimated $11.3M and leaving 702,858 shares worth $17.2M. The position accounts for 0.02% of the portfolio, ranked #793.

Dmitry Balyasny first reported a position in BIOA in Q3 2024 and has held it in 3 quarters since. The position peaked at $23.2M in Q1 2026. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Dmitry Balyasny held 702,858 shares of BioAge Labs worth $17.2M as of Q2 2026.
  • Dmitry Balyasny sold 624,687 BioAge Labs shares in Q2 2026, an estimated $11.3M.
  • BioAge Labs made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #793 holding.
  • Dmitry Balyasny first reported a position in BioAge Labs in Q3 2024 and has held it in 3 quarters since.
  • Dmitry Balyasny's BioAge Labs position peaked at $23.2M in Q1 2026.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.